




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/527,742	Manuel Sarasa Barrio	100878.56050US



INTERNATIONAL APPLICATION NO.

PCT/ES03/00422

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

08/13/2003

09/12/2002

23911

CROWELL & MORING LLP

INTELLECTUAL PROPERTY ACTION

P.O. BOX 14300

WASHINGTON, DC 20044-4300

Notice to Comply
Due Date 10/9/06
Docket # 56050US
Attorney CTM
Docketing 8/14/06

CONFIRMATION NO. 9149

371 FORMALITIES LETTER



OC000000019952380

Date Mailed: 08/09/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*


MAMIE P PERSON

Telephone: (703) 308-9140 EXT 227

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/527,742	PCT/ES03/00422	100878.56050US

FORM PCT/DO/EO/922 (371 Formalities Notice)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/527,742 Confirmation No. : 9149
First Named Inventor : Manuel Sarasa BARRIO
Filed : March 14, 2005
TC/A.U. : Unassigned

Docket No. : 100878.56050US
Customer No. : 23911

Title : Polyclonal Antibodies, Preparation Method Thereof and Use
of Same

Mail Stop SEQUENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION TO COMPLY

Sir:

Attached hereto please find:


1. A copy of the Notification to Comply with Requirements for Patent Applications dated August 9, 2006.
2. Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-1.825.
3. 1 CRF of sequence listing.
4. Paper copy of sequence listing.

This filing and the associated attachments are responsive to the Notification to Comply and are believed to put the sequence listing and specification in proper form.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #100878.56050US).

October 10, 2006

Respectfully submitted,



James F. McKeown
Registration No. 25,406

Christopher T. McWhinney
Registration No. 42,875

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JFM:CTM:mdm (2867517)